Morphological and morphometric analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a retrospective study

被引:11
|
作者
Filoni, A. [1 ,2 ]
Cicco, G. [1 ]
Lospalluti, L. [1 ]
Maglietta, A. [3 ]
Foti, C. [1 ]
Annichiarico, G. [4 ]
Resta, L. [3 ]
Bonamonte, D. [1 ]
机构
[1] Univ Bari, Sect Dermatol, Dept Biomed Sci & Human Oncol, Bari, Italy
[2] San Gallicano Dermatol Inst IRCCS, Rome, Italy
[3] Univ Bari, Dept Emergency & Organ Transplantat, Sect Pathol, Bari, Italy
[4] AReS Puglia, Reg Coordinat Rare Dis, Bari, Italy
关键词
GROWTH-FACTOR; FORMS; RISK;
D O I
10.1111/jdv.16022
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Recessive dystrophic epidermolysis bullosa is a highly disabling genodermatosis characterized by skin and mucosal fragility and blistering. Cutaneous squamous cell carcinoma (cSCC) is one of the most devastating complications, having a high morbidity and mortality rate. Patients with recessive dystrophic epidermolysis bullosa were reported to have up to a 70-fold higher risk of developing cSCC than unaffected individuals. Immune cells play a role in cancer evolution. Objective The aim of our study was to evaluate immunohistological differences between cSCC in patients with and without recessive dystrophic epidermolysis bullosa. Methods A retrospective study of 25 consecutive cases was performed; five were biopsies of cSCC taken from five patients with recessive dystrophic epidermolysis bullosa; as controls we analysed 10 cSCC in subjects without recessive dystrophic epidermolysis bullosa (5 primitive, 3 postburns and 2 postradiotherapy), 5 cSCC in renal transplant recipients and 5 cutaneous pseudoepitheliomatous hyperplasia in patients with recessive dystrophic epidermolysis bullosa. Results A significant reduction of CD3+, CD4+ and CD68+ between the cSCC in patients with recessive dystrophic epidermolysis bullosa compared to primary cSCC and a significant reduction of CD3+, CD4+, CD8+ and CD20+ were observed in cSCC in patients with recessive dystrophic epidermolysis bullosa compared to secondary cSCC. On the contrary, there was no difference in CD3+, CD8+, CD20+ and CD68+ expression when comparing cSCC in patients with recessive dystrophic epidermolysis bullosa to cSCC in renal transplant recipients. No significant difference was found in size, histopathology, grading, number of mitoses and EGFR expression between the different groups. Conclusions Our data show a reduction in immune cell peritumoral infiltration. Considering the well-known evolution of cSCC in patients with recessive dystrophic epidermolysis bullosa, as well as the younger age at diagnosis, it can be assumed that immune dysfunction might contribute to the cSCC aggressiveness in these patients.
引用
收藏
页码:1707 / 1714
页数:8
相关论文
共 50 条
  • [31] Raman spectroscopy for detection of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa skin
    Dimitrievska, Marija
    Chiappini, Ciro
    Mcgrath, John
    Bergholt, Mads S.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (06) : e79 - e79
  • [32] Sentinel lymph node biopsy in recessive dystrophic epidermolysis bullosa and squamous cell carcinoma
    Perez-Naranjo, L
    Herrera-Saval, A
    Garcia-Bravo, B
    Perez-Bernal, AM
    Camacho, F
    ARCHIVES OF DERMATOLOGY, 2005, 141 (01) : 110 - 111
  • [33] Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa
    Vasilev, Preslav
    Kalev, Dimitar
    Karamanliev, Martin
    Dimitrov, Dobromir
    Troyanova, Petranka
    Yordanova, Ivelina
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 (03): : 295 - 297
  • [34] Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa: report of eight tumours in four patients
    Bosch, RJ
    Gallardo, MA
    del Portal, GR
    Sánchez, P
    Arce, MF
    Herrera, E
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 1999, 13 (03) : 198 - 204
  • [35] Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa
    Piccerillo, Alfredo
    El Hachem, Maya
    De Vito, Rita
    De Luca, Erika Valentina
    Peris, Ketty
    JAMA DERMATOLOGY, 2020, 156 (06) : 708 - 710
  • [36] Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa-Associated- Associated Cutaneous Squamous Cell Carcinoma
    Lee, Catherine A. A.
    Wu, Siyuan
    Chow, Yuen Ting
    Kofman, Eric
    Williams, Valencia
    Riddle, Megan
    Eide, Cindy
    Ebens, Christen L.
    Frank, Markus H.
    Tolar, Jakub
    Hook, Kristen P.
    Aldubayan, Saud H.
    Frank, Natasha Y.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (07) : 1534 - 1543.e2
  • [37] Expression of matrilysin-1 (MMP-7) in cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa
    Kivisaari, A
    McGrath, JA
    Bauer, JW
    Konigova, R
    Sawamura, D
    Sato-Matsumura, KC
    Kähäri, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (02)
  • [38] Fibroblast-Derived Dermal Matrix Drives Development of Aggressive Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa
    Yi-Zhen Ng
    Pourreyron, Celine
    Salas-Alanis, Julio C.
    Dayal, Jasbani H. S.
    Cepeda-Valdes, Rodrigo
    Yan, Wenfei
    Wright, Sheila
    Chen, Mei
    Fine, Jo-David
    Hogg, Fiona J.
    McGrath, John A.
    Murrell, Dedee F.
    Leigh, Irene M.
    Lane, E. Birgit
    South, Andrew P.
    CANCER RESEARCH, 2012, 72 (14) : 3522 - 3534
  • [39] Rigosertib demonstrates considerable efficacy and safety in the treatment of advanced/metastatic cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa
    Laimer, M.
    South, A.
    Yang, H. Y.
    Banner, L.
    Mayr, E.
    Kitzmueller, S.
    Parris, M.
    Arora, M.
    Bauer, J.
    Nikbakht, N.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S50 - S50
  • [40] Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa
    Weber, F
    Bauer, JW
    Sepp, N
    Högler, W
    Salmhofer, W
    Hintner, H
    Fritsch, P
    ACTA DERMATO-VENEREOLOGICA, 2001, 81 (03) : 189 - 192